{"id":89890,"date":"2020-10-23T06:05:48","date_gmt":"2020-10-23T11:05:48","guid":{"rendered":"https:\/\/PERSIAN-HERITAGE.COM\/?p=89890"},"modified":"2020-10-23T06:05:48","modified_gmt":"2020-10-23T11:05:48","slug":"auto-draft-277","status":"publish","type":"post","link":"https:\/\/PERSIAN-HERITAGE.COM\/en\/2020\/10\/23\/auto-draft-277\/","title":{"rendered":"Moderna Enrolls 30,000 Diverse Americans in Phase 3 Trials"},"content":{"rendered":"
\n
\n
\n

\"\"VOA \u2014 Moderna Therapeutics, one of many companies conducting COVID-19 vaccine trials, said Thursday that it had completed the enrollment of about 30,000 participants for a third phase. The biotechnology firm said the participants included more than 11,000 who are people of color.<\/p>\n

The figure includes more than 6,000 Hispanic participants and 3,000 African Americans. Moderna said these two groups represented 37% of the study population, which reflects the diversity of the U.S. at large.<\/p>\n

\n
\n
\n
\"Moderna<\/div>\n<\/figure>\n<\/div>
Moderna CEO Stephane Bancel speaks at a meeting with President Donald Trump, March 2, 2020, in Washington.<\/figcaption><\/figure>\n

Moderna Chief Executive Officer St\u00e9phane Bancel thanked participants and said assembling the enrollment for Phase 3 of its COVE study is an \u201cimportant milestone for the clinical development of mRNA-1273, our vaccine candidate against COVID-19.\u201d<\/p>\n

Other participants include Americans at high risk medically over age\u00a065 and a younger population with chronic health problems, such as diabetes, severe obesity\u00a0and cardiac issues. These high-risk groups represent 42% of the total participants in the company\u2019s Phase 3 COVE study.<\/p>\n

The randomized, placebo-controlled Phase 3 trial is studying mRNA-1273 at the 100-microgram-dose level in all 30,000 participants.<\/p>\n

So far, more than 25,650 participants have received their second vaccinations. Moderna has not yet applied to the FDA for Emergency Use Authorization.<\/p>\n

\u201cModerna is committed to rigorous scientific research and the highest data quality standards. We will continue to work in collaboration with regulators to advance mRNA-1273, which we hope will help defeat the COVID-19 pandemic,\u201d Bancel said.<\/p>\n

The vaccine manufacturer worked closely with the Biomedical Advanced Research Development Authority (BARDA) and two other institutions to conduct the Phase 3 COVE study under Operation Warp Speed.<\/p>\n

BARDA is supporting the continued research and development of the vaccine with $955 million in federal funding. The U.S. government has committed up to $1.525 billion to purchase a supply of the vaccine.<\/p>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

VOA \u2014 Moderna Therapeutics, one of many companies conducting COVID-19 vaccine trials, said Thursday that it had completed the enrollment of about 30,000 participants for a third phase. The biotechnology firm said the participants included more than 11,000 who are people of color. The figure includes more than 6,000 Hispanic participants and 3,000 African Americans. […]<\/p>\n","protected":false},"author":1,"featured_media":89891,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[10],"tags":[],"class_list":["post-89890","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-latests"],"translation":{"provider":"WPGlobus","version":"3.0.2","language":"en","enabled_languages":["fa","en"],"languages":{"fa":{"title":true,"content":false,"excerpt":false},"en":{"title":true,"content":true,"excerpt":false}}},"_links":{"self":[{"href":"https:\/\/PERSIAN-HERITAGE.COM\/en\/wp-json\/wp\/v2\/posts\/89890","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/PERSIAN-HERITAGE.COM\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/PERSIAN-HERITAGE.COM\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/PERSIAN-HERITAGE.COM\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/PERSIAN-HERITAGE.COM\/en\/wp-json\/wp\/v2\/comments?post=89890"}],"version-history":[{"count":2,"href":"https:\/\/PERSIAN-HERITAGE.COM\/en\/wp-json\/wp\/v2\/posts\/89890\/revisions"}],"predecessor-version":[{"id":89893,"href":"https:\/\/PERSIAN-HERITAGE.COM\/en\/wp-json\/wp\/v2\/posts\/89890\/revisions\/89893"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/PERSIAN-HERITAGE.COM\/en\/wp-json\/wp\/v2\/media\/89891"}],"wp:attachment":[{"href":"https:\/\/PERSIAN-HERITAGE.COM\/en\/wp-json\/wp\/v2\/media?parent=89890"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/PERSIAN-HERITAGE.COM\/en\/wp-json\/wp\/v2\/categories?post=89890"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/PERSIAN-HERITAGE.COM\/en\/wp-json\/wp\/v2\/tags?post=89890"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}